China's Asieris Pharma Completes C Round for Genito-Urinary Tumor Treatments
publication date: Mar 26, 2020
Asieris Pharma, located in Taizhou's China Medical City, closed a C round to advance its genito-urinary tumor treatments. In 2019, its lead candidate, a novel treatment for non-muscular invasive bladder cancer, completed patient enrollment in a China Phase III trial. Unlike other treatments for the condition, usually bladder resection, APL-1202 is convenient, painless and does not cause damage to the urethra. A repurposed oral inhibitor of MetAP2, APL-1202 is a 50-year-old wide spectrum antibiotic that had been shown to have an anti-angiogenesis effect. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.